RE:RE:RE:RE:RE:RE:Resistance to ADCs in the treatment of solid tumors ADCs with endocrine therapies, immunotherapies, or PARP inhibitors may have a synergistic effect without a serious increase in toxicity, according to Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN.
Immunotherapies, (i.e ONCY's pelareorep), in combination with ADCs, are a novel class of therapies that are particularly well suited in combination with ADCs, and do not add over-lapping toxcities, as some other classes of therapies do.
https://www.youtube.com/watch?v=i5Kl3hxnCAE&ab_channel=VJOncology